---
title: "Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287274290.md"
description: "Sensei Biotherapeutics plans to convert Series B preferred shares into common stock, seeking stockholder approval at the annual meeting on June 10, 2026. The pro forma shows 25.7M weighted shares and $184.57M in equity, with a reduction in pro forma net loss per share from $(131.45) to $(6.62). This includes the acquisition of Faeth and a $200M PIPE closed on February 20, 2026."
datetime: "2026-05-21T21:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287274290.md)
  - [en](https://longbridge.com/en/news/287274290.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287274290.md)
---

# Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity

**Sensei Biotherapeutics will seek stockholder approval to convert Series B preferred into common, with unaudited pro forma showing 25.7M weighted shares and $184.57M equity.**

**Key Highlights:**

-   Annual meeting set for June 10, 2026 to vote on conversion of Series B preferred that would exceed 20% and effect change of control.
-   Pro forma balance sheet assumes conversion of 24,434,920 Series B preferred into common, resulting in $184.57M stockholders’ equity.
-   Pro forma weighted-average shares rise to 25,729,972, reducing pro forma net loss per share to $(6.62) from $(131.45).
-   Acquisition of Faeth reflected: 10,497,098 Series B issued in merger and $200M PIPE (14,440,395 as-converted) closed Feb 20, 2026.

Original SEC Filing: Sensei Biotherapeutics, Inc. \[ SNSE \] - 8-K - May. 21, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SNSE.US](https://longbridge.com/en/quote/SNSE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Sensei Biotherapeutics Insiders Sold Shares Worth Over $1.0M](https://longbridge.com/en/news/288331208.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Has the bull market shifted to biotech stocks?](https://longbridge.com/en/news/293077044.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position](https://longbridge.com/en/news/286559285.md)